Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Neuronal plasticity and neurotrophic factors in drug responses.

Castrén E, Antila H.

Mol Psychiatry. 2017 Aug;22(8):1085-1095. doi: 10.1038/mp.2017.61. Epub 2017 Apr 11.

PMID:
28397840
2.

The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: A systematic review and meta-analysis.

Moraros J, Nwankwo C, Patten SB, Mousseau DD.

Depress Anxiety. 2017 Mar;34(3):217-226. doi: 10.1002/da.22584. Epub 2016 Dec 28.

3.

Association between Stroke Status and Depression in a Community Setting: The 2014 Korea National Health and Nutrition Examination Survey.

Kim M, Oh GJ, Lee YH.

J Clin Neurol. 2017 Jan;13(1):55-61. doi: 10.3988/jcn.2017.13.1.55. Epub 2016 Nov 17.

4.

Relearning to See in Cortical Blindness.

Melnick MD, Tadin D, Huxlin KR.

Neuroscientist. 2016 Apr;22(2):199-212. doi: 10.1177/1073858415621035. Epub 2015 Dec 10. Review. Erratum in: Neuroscientist. 2016 Apr;22(2):213.

5.

Drugs to Enhance Motor Recovery After Stroke.

Cramer SC.

Stroke. 2015 Oct;46(10):2998-3005. doi: 10.1161/STROKEAHA.115.007433. Epub 2015 Aug 11. Review. No abstract available.

6.

Post-stroke depression and the aging brain.

Cojocaru GR, Popa-Wagner A, Stanciulescu EC, Babadan L, Buga AM.

J Mol Psychiatry. 2013 Aug 23;1(1):14. doi: 10.1186/2049-9256-1-14. eCollection 2013. Review.

7.

Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia.

Liu X, Zhang J, Sun D, Fan Y, Zhou H, Fu B.

Clin Interv Aging. 2014 Mar 10;9:411-8. doi: 10.2147/CIA.S58830. eCollection 2014.

8.

A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design.

Guekht A, Skoog I, Korczyn AD, Zakharov V, Eeg M, Vigonius U.

Dement Geriatr Cogn Dis Extra. 2013 Dec 14;3(1):459-67. doi: 10.1159/000357122. eCollection 2013 Jan.

9.

Management of patients with stroke: is it time to expand treatment options?

Adams HP Jr, Nudo RJ.

Ann Neurol. 2013 Jul;74(1):4-10. doi: 10.1002/ana.23948. Epub 2013 Aug 6.

10.

Treatment of neurodevelopmental disorders in adulthood.

Castrén E, Elgersma Y, Maffei L, Hagerman R.

J Neurosci. 2012 Oct 10;32(41):14074-9. doi: 10.1523/JNEUROSCI.3287-12.2012. Review.

11.

Post-stroke depression: mechanisms, translation and therapy.

Loubinoux I, Kronenberg G, Endres M, Schumann-Bard P, Freret T, Filipkowski RK, Kaczmarek L, Popa-Wagner A.

J Cell Mol Med. 2012 Sep;16(9):1961-9. doi: 10.1111/j.1582-4934.2012.01555.x. Review.

12.

Exploring new frontiers in neuropsychopharmacology: SSRIs for stroke.

Sathyanarayana Rao TS, Andrade C.

Indian J Psychiatry. 2011 Oct;53(4):283-6. doi: 10.4103/0019-5545.91899. No abstract available.

13.

Depression, strokes and dementia: new biological insights into an unfortunate pathway.

Hakim AM.

Cardiovasc Psychiatry Neurol. 2011;2011:649629. doi: 10.1155/2011/649629. Epub 2011 Dec 15.

14.

Increased frequency of first-episode poststroke depression after discontinuation of escitalopram.

Mikami K, Jorge RE, Moser DJ, Arndt S, Jang M, Solodkin A, Small SL, Fonzetti P, Hegel MT, Robinson RG.

Stroke. 2011 Nov;42(11):3281-3. doi: 10.1161/STROKEAHA.111.626507. Epub 2011 Aug 25.

15.

Vascular cognitive impairment: disease mechanisms and therapeutic implications.

Levine DA, Langa KM.

Neurotherapeutics. 2011 Jul;8(3):361-73. doi: 10.1007/s13311-011-0047-z. Review.

16.

Poststroke depression and treatment effects on functional outcomes.

Schmid AA, Kroenke K, Hendrie HC, Bakas T, Sutherland JM, Williams LS.

Neurology. 2011 Mar 15;76(11):1000-5. doi: 10.1212/WNL.0b013e318210435e.

17.

Cognitive enhancement by drugs in health and disease.

Husain M, Mehta MA.

Trends Cogn Sci. 2011 Jan;15(1):28-36. doi: 10.1016/j.tics.2010.11.002. Epub 2010 Dec 9. Review.

Supplemental Content

Support Center